𝗟𝘂𝗺𝗶𝗻𝗮𝗿𝘆 𝗚𝗿𝗼𝘂𝗽, 𝗚𝗹𝗼𝗯𝗮𝗹 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝗰𝘆 #artificialintelligence #realworlddata #mergersandacquisitions #realworldevidence #productlifecycle #regulatory #pharmacovigilence #bioprocessing #cdmo #clinicaltrials #consultancy #eclinical #saas #ecoa
About us
Luminary Group, headquartered at St Magnus House, 3 Lower Thames Street, Central London, EC3R 6HD, is an international executive search and business consultancy specializing in the Life Sciences and Pharmaceutical sectors. Our expertise lies within the Real World Evidence, eClinical, Artificial Intelligence, Consulting and Biotechnology disciplines with localized insights and specialized knowledge. Executive Search - Tailored executive search solutions to identify and recruit top talent for key leadership positions ranging from Chairman, Board, CEO, CCO, COO, CPO - AVP Design and Recruitment for Commercial Team Organization -Strategic planning and talent acquisition services to build high-performing commercial teams aligned with business goals. Design and Recruitment for Operations Team Organization -Expert guidance in structuring and staffing operations teams for efficient and effective business operations. Data Partnerships, Business Partnerships and M&A Consulting -Advisory assistance in forging data partnerships, leveraging our extensive network of leading RWE, RWD, and AI enterprises across the US and Europe. Additionally, we aid in cultivating business collaborations with biotechnology firms and guiding through mergers and acquisitions to foster growth and innovation. Operating globally with a presence in the USA, Europe, APAC, and the Middle East, we take pride in our exclusive talent pool, ranging from C-Suite to Managerial levels, and our exclusive partnerships with returning clients and candidates. Our collaborations extend across a diverse range of companies, from Corporate to innovative Start-Ups. For additional details, please explore our website: www.luminarygroup.co.uk
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
City of London , GB
Employees at Luminary Group
Updates
-
𝗝𝗣𝗠’𝘀 𝗹𝗶𝗳𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗩𝗖 𝘁𝗲𝗮𝗺 𝗶𝘀 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 J.P. Morgan SAMARTH LIFE SCIENCES PRIVATE LIMITED hired a leading biotech investor as it continues to build out its team after having disclosed two recent investments … https://lnkd.in/dMTzgY7V
-
𝗜𝗹𝗹𝘂𝗺𝗶𝗻𝗮 𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗼𝗿 𝗘𝗹𝗲𝗺𝗲𝗻𝘁 𝗕𝗶𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟮𝟳𝟳𝗠 𝗶𝗻 𝗦𝗲𝗿𝗶𝗲𝘀 𝗗 Element Biosciences has raised an additional $277 million in private financing to support commercialization of its benchtop DNA sequencer and an instrument launch as the https://lnkd.in/dt6_STJ3
Illumina competitor Element Biosciences raises $277M in Series D
https://endpts.com
-
𝗨𝗻𝘃𝗲𝗹𝗹𝗶𝗻𝗴 𝗥𝗲𝗰𝗲𝗻𝘁 𝗙𝘂𝗻𝗱𝗶𝗻𝗴, 𝗠&𝗔 𝗮𝗻𝗱 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀-𝗝𝘂𝗹𝘆 𝟮𝟬𝟮𝟰 Sanofi plans to invest €1.5 billion in its Frankfurt plant, reversing plans to relocate production to France. Eli Lilly and Company invests $140 million upfront in Radionetics Oncology, with an option to acquire the company for $1 billion. GSK acquires CureVac's mRNA flu and COVID-19 vaccines for €400 million upfront, with potential payments up to €1.05 billion. Emergent BioSolutions secures over $250 million from the US for strategic stockpile vaccines and treatments. Beacon Therapeutics raises $170 million to advance its lead eye disease therapy in clinical trials. Exsilio Therapeutics, led by a former Moderna exec, launches with $82 million to tackle genetic medicine challenges. Moderna secures $176 million from BARDA to develop a bird flu vaccine using mRNA technology. Cartesian Therapeutics raises $130 million through PIPE financing and reports positive Phase 2b trial results for myasthenia gravis treatment. Eli Lilly and Company's Alzheimer's Association® drug Kisunla™ (donanemab-azbt) HCP gains FDAQRC approval, offering monthly treatment for cognitive decline, priced at $32,000 per year. Novo Nordisk invests $4.1 billion in a new plant in North Carolina, creating 1,000 jobs to produce obesity and chronic disease treatment. Sanofi looking to sell its consumer healthcare division, Opella-hospitality valued at $20 billion. ANI Pharmaceuticals, Inc. acquires Alimera Alimera Sciences Ophthalmologie GmbH GmbH for $381 million. AbbVie acquires Celsius Therapeutics for $250 million, gaining a Phase I candidate drug for inflammatory bowel disease. Alumis raises $210 million in a major IPO, but below expectations, supported by a $40 million private stock sale. Roche partners with Ascidian Therapeutics to target neurological diseases, potentially paying up to $1.8 billion plus royalties. EUROAPI plans €350-400 million investment, including Sanofi support, with restructuring and job cuts to focus on high-value APIs.
-
A fantastic testimonial for our Senior Partner here at Luminary Group, Serena Vigano... "Serena helped me replacing a key role. To make the story short, I can truly say that she is one of the very few recruiters I will contact for any further need. Client focused, efficient, diligent, she has worked tirelessly until we found the right person. I recently needed a very urgent support and she made herself available and started working on it literally in few hours. She is the go to person. A true finisher.”, CEO Pharmaceutical Company. Contact Serena for exciting opportunities in Clinical Operations, Regulatory Affairs, and Quality Assurance! #regulatoryaffairs #medicalaffairs #qualityassurance #medicaldevices #pharmaceutical #cellandgenetherapy
-
𝗣𝗳𝗶𝘇𝗲𝗿 𝗽𝗿𝗲𝘀𝘀𝗲𝘀 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 𝘄𝗶𝘁𝗵 𝗼𝗻𝗰𝗲-𝗱𝗮𝗶𝗹𝘆 𝗚𝗟𝗣-𝟭 𝗽𝗶𝗹𝗹 𝗶𝗻 𝗹𝗼𝗻𝗴-𝗮𝘄𝗮𝗶𝘁𝗲𝗱 𝗺𝗼𝘃𝗲 Pfizer is making a move on its obesity pipeline after multiple quarters of questions from investors and analysts. Albert Bourla https://lnkd.in/dxdSwrkK
Pfizer’s once-daily oral GLP-1 drug passes first clinical tests
https://endpts.com
-
𝗡𝗼𝘃𝗼-𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝗲𝗱 𝟯𝗗 𝗯𝗶𝗼𝗽𝗿𝗶𝗻𝘁𝗶𝗻𝗴 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗴𝗲𝘁𝘀 $𝟳𝟬𝗠+ 𝗳𝗿𝗼𝗺 𝗖𝗮𝗻𝗮𝗱𝗶𝗮𝗻 𝗴𝗼𝘃𝗲𝗿𝗻𝗺𝗲𝗻𝘁 Aspect Biosystems has received $72.75 million in funding from the governments of Canada and British Columbia to advance its pipeline of preclinical 3D-printed tissue candidates …Tamer Mohamed https://lnkd.in/dB8Z_xY9
Novo-partnered Aspect Biosystems gets $70M+ cash injection from Canadian government
https://endpts.com
-
𝗖𝗠𝗦 𝗿𝗼𝗹𝗹𝘀 𝗼𝘂𝘁 𝗽𝗼𝗹𝗶𝗰𝘆 𝗽𝗿𝗼𝗽𝗼𝘀𝗮𝗹𝘀 𝗼𝗻 𝗻𝗼𝗻-𝗼𝗽𝗶𝗼𝗶𝗱 𝗱𝗿𝘂𝗴𝘀, 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮���𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 — 𝗟𝗮𝗻𝘁𝗵𝗲𝘂𝘀 𝘀𝘁𝗼𝗰𝗸 𝗷𝘂𝗺𝗽𝘀 The Centers for Medicare & Medicaid Services on Wednesday outlined a series of proposed policy changes for next year that would …Chiquita Brooks-LaSure https://lnkd.in/d9fDRtVC
CMS rolls out policy proposals on non-opioid drugs, radiopharmaceuticals — Lantheus stock jumps
https://endpts.com
-
𝗨𝗻𝗶𝗤𝘂𝗿𝗲 𝘁𝗿𝘂𝗺𝗽𝗲𝘁𝘀 𝗺𝗶𝗱-𝘀𝘁𝗮𝗴𝗲 𝗱𝗮𝘁𝗮 𝗳𝗼𝗿 𝗛𝘂𝗻𝘁𝗶𝗻𝗴𝘁𝗼𝗻'𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 uniQure on Tuesday released new two-year data on its Huntington’s disease gene therapy called AMT-130, sending its stock $QURE up by …Matthew Kapusta https://lnkd.in/dqv4tKVb
UniQure trumpets mid-stage data for Huntington’s disease gene therapy
https://endpts.com
-
𝗙𝗹𝗮𝗴𝘀𝗵𝗶𝗽 𝗿𝗲𝗲𝗹𝘀 𝗶𝗻 $𝟯.𝟲𝗕 𝘁𝗼 𝗰𝗿𝗲𝗮𝘁𝗲 𝟮𝟱 𝗻𝗲𝘄 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 Flagship Pioneering,the 25-year-old life sciences incubator and investor, has reeled in $3.6 billion to build another 25 or so companies, it. Noubar Afeyan https://lnkd.in/dT7Sy5rt
Flagship raises $3.6B for 25 new startups
https://endpts.com